BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-705@pharmaconomics
DTSTAMP:20260707T034028Z
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260320
SUMMARY:RYTM Approval — IMCIVREE (setmelanotide)
DESCRIPTION:A final FDA approval decision on IMCIVREE (setmelanotide) for acquired hypothalamic obesity is expected Mar 19\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm\n\nTrack it: https://www.pharmaconomics.com/e/705
URL:https://www.pharmaconomics.com/e/705
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RYTM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR